vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and Smart Sand, Inc. (SND). Click either name above to swap in a different company.

Smart Sand, Inc. is the larger business by last-quarter revenue ($86.0M vs $74.7M, roughly 1.2× Health Catalyst, Inc.). Smart Sand, Inc. runs the higher net margin — 1.4% vs -121.9%, a 123.3% gap on every dollar of revenue. On growth, Smart Sand, Inc. posted the faster year-over-year revenue change (-5.8% vs -6.2%). Smart Sand, Inc. produced more free cash flow last quarter ($20.4M vs $9.6M). Over the past eight quarters, Smart Sand, Inc.'s revenue compounded faster (1.8% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Sand 9 is a fabless Micro-electromechanical system (MEMS) company based in Cambridge, Massachusetts. Sand 9 developed a piezoelectric MEMS resonator to serve as an alternative for quartz timing devices in applications such as smart phones, low-power wireless devices, and communications infrastructure equipment.

HCAT vs SND — Head-to-Head

Bigger by revenue
SND
SND
1.2× larger
SND
$86.0M
$74.7M
HCAT
Growing faster (revenue YoY)
SND
SND
+0.4% gap
SND
-5.8%
-6.2%
HCAT
Higher net margin
SND
SND
123.3% more per $
SND
1.4%
-121.9%
HCAT
More free cash flow
SND
SND
$10.7M more FCF
SND
$20.4M
$9.6M
HCAT
Faster 2-yr revenue CAGR
SND
SND
Annualised
SND
1.8%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
SND
SND
Revenue
$74.7M
$86.0M
Net Profit
$-91.0M
$1.2M
Gross Margin
13.0%
Operating Margin
-115.3%
-3.1%
Net Margin
-121.9%
1.4%
Revenue YoY
-6.2%
-5.8%
Net Profit YoY
-340.3%
-68.5%
EPS (diluted)
$-1.29
$0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
SND
SND
Q4 25
$74.7M
$86.0M
Q3 25
$76.3M
$92.8M
Q2 25
$80.7M
$85.8M
Q1 25
$79.4M
$65.6M
Q4 24
$79.6M
$91.4M
Q3 24
$76.4M
$63.2M
Q2 24
$75.9M
$73.8M
Q1 24
$74.7M
$83.1M
Net Profit
HCAT
HCAT
SND
SND
Q4 25
$-91.0M
$1.2M
Q3 25
$-22.2M
$3.0M
Q2 25
$-41.0M
$21.4M
Q1 25
$-23.7M
$-24.2M
Q4 24
$-20.7M
$3.7M
Q3 24
$-14.7M
$-98.0K
Q2 24
$-13.5M
$-430.0K
Q1 24
$-20.6M
$-216.0K
Gross Margin
HCAT
HCAT
SND
SND
Q4 25
13.0%
Q3 25
52.6%
16.1%
Q2 25
10.4%
Q1 25
4.2%
Q4 24
14.7%
Q3 24
47.5%
10.3%
Q2 24
17.7%
Q1 24
14.2%
Operating Margin
HCAT
HCAT
SND
SND
Q4 25
-115.3%
-3.1%
Q3 25
-22.9%
5.8%
Q2 25
-46.0%
-0.1%
Q1 25
-25.4%
-10.8%
Q4 24
-22.0%
3.9%
Q3 24
-17.9%
-7.8%
Q2 24
-20.8%
4.8%
Q1 24
-30.5%
0.9%
Net Margin
HCAT
HCAT
SND
SND
Q4 25
-121.9%
1.4%
Q3 25
-29.1%
3.2%
Q2 25
-50.8%
24.9%
Q1 25
-29.9%
-37.0%
Q4 24
-26.0%
4.1%
Q3 24
-19.3%
-0.2%
Q2 24
-17.8%
-0.6%
Q1 24
-27.6%
-0.3%
EPS (diluted)
HCAT
HCAT
SND
SND
Q4 25
$-1.29
$0.03
Q3 25
$-0.32
$0.08
Q2 25
$-0.59
$0.54
Q1 25
$-0.35
$-0.62
Q4 24
$-0.33
$0.10
Q3 24
$-0.24
$0.00
Q2 24
$-0.23
$-0.01
Q1 24
$-0.35
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
SND
SND
Cash + ST InvestmentsLiquidity on hand
$95.7M
$22.6M
Total DebtLower is stronger
$153.3M
$15.0M
Stockholders' EquityBook value
$245.8M
$239.7M
Total Assets
$502.6M
$340.0M
Debt / EquityLower = less leverage
0.62×
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
SND
SND
Q4 25
$95.7M
$22.6M
Q3 25
$91.5M
$5.1M
Q2 25
$97.3M
$4.3M
Q1 25
$342.0M
$5.1M
Q4 24
$392.0M
$1.6M
Q3 24
$387.3M
$7.2M
Q2 24
$308.3M
$6.3M
Q1 24
$327.8M
$4.6M
Total Debt
HCAT
HCAT
SND
SND
Q4 25
$153.3M
$15.0M
Q3 25
$153.1M
$14.3M
Q2 25
$153.0M
$23.5M
Q1 25
$382.9M
$13.7M
Q4 24
$382.4M
$14.7M
Q3 24
$345.0M
$15.7M
Q2 24
$17.1M
Q1 24
$25.5M
Stockholders' Equity
HCAT
HCAT
SND
SND
Q4 25
$245.8M
$239.7M
Q3 25
$331.9M
$239.9M
Q2 25
$347.5M
$240.5M
Q1 25
$376.8M
$219.9M
Q4 24
$365.2M
$243.8M
Q3 24
$355.0M
$243.6M
Q2 24
$357.0M
$242.9M
Q1 24
$357.2M
$242.5M
Total Assets
HCAT
HCAT
SND
SND
Q4 25
$502.6M
$340.0M
Q3 25
$587.1M
$343.1M
Q2 25
$616.2M
$345.8M
Q1 25
$891.5M
$326.9M
Q4 24
$858.9M
$341.5M
Q3 24
$813.0M
$335.8M
Q2 24
$691.7M
$341.8M
Q1 24
$695.1M
$349.3M
Debt / Equity
HCAT
HCAT
SND
SND
Q4 25
0.62×
0.06×
Q3 25
0.46×
0.06×
Q2 25
0.44×
0.10×
Q1 25
1.02×
0.06×
Q4 24
1.05×
0.06×
Q3 24
0.97×
0.06×
Q2 24
0.07×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
SND
SND
Operating Cash FlowLast quarter
$9.9M
$22.4M
Free Cash FlowOCF − Capex
$9.6M
$20.4M
FCF MarginFCF / Revenue
12.9%
23.7%
Capex IntensityCapex / Revenue
0.4%
2.3%
Cash ConversionOCF / Net Profit
18.99×
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$32.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
SND
SND
Q4 25
$9.9M
$22.4M
Q3 25
$-464.0K
$18.2M
Q2 25
$-9.0M
$-5.1M
Q1 25
$280.0K
$8.7M
Q4 24
$-3.5M
$1.0M
Q3 24
$6.2M
$5.8M
Q2 24
$1.6M
$14.9M
Q1 24
$10.3M
$-3.9M
Free Cash Flow
HCAT
HCAT
SND
SND
Q4 25
$9.6M
$20.4M
Q3 25
$-719.0K
$14.8M
Q2 25
$-9.2M
$-7.8M
Q1 25
$-390.0K
$5.2M
Q4 24
$-3.9M
$-840.0K
Q3 24
$5.5M
$3.7M
Q2 24
$1.3M
$13.5M
Q1 24
$10.1M
$-5.5M
FCF Margin
HCAT
HCAT
SND
SND
Q4 25
12.9%
23.7%
Q3 25
-0.9%
15.9%
Q2 25
-11.4%
-9.1%
Q1 25
-0.5%
7.9%
Q4 24
-4.9%
-0.9%
Q3 24
7.2%
5.8%
Q2 24
1.7%
18.3%
Q1 24
13.5%
-6.6%
Capex Intensity
HCAT
HCAT
SND
SND
Q4 25
0.4%
2.3%
Q3 25
0.3%
3.6%
Q2 25
0.3%
3.1%
Q1 25
0.8%
5.4%
Q4 24
0.5%
2.1%
Q3 24
0.9%
3.4%
Q2 24
0.4%
1.8%
Q1 24
0.3%
2.0%
Cash Conversion
HCAT
HCAT
SND
SND
Q4 25
18.99×
Q3 25
6.05×
Q2 25
-0.24×
Q1 25
Q4 24
0.28×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

SND
SND

Sand$85.1M99%
Smart Systems Segment$980.0K1%

Related Comparisons